MorphoSys AG buy KirDa
Summary
This prediction ended on 17.07.23 with a price of €27.52. With a performance of 93.80% the BUY prediction by KirDa was a big success. This prediction was marked as speculative and is excluded from KirDa's performance statistics.MorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
MorphoSys AG | -3.542% | -3.542% | 243.495% |
iShares Core DAX® | -0.992% | -3.231% | 11.661% |
iShares Nasdaq 100 | -0.225% | -3.339% | 36.491% |
iShares Nikkei 225® | -0.736% | -7.859% | 18.597% |
iShares S&P 500 | -0.509% | -2.979% | 26.341% |
Comments by KirDa for this prediction
In the thread Morphosys AG diskutieren